Subscribe to our Email Alerts

Investor Fact Sheet

Company Name: Amplia Therapeutics Limited (ACN 165 160 841)

Business Description:

Amplia Therapeutics Limited (ASX: ATX) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Innate has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).


Shares on Issue: 41,023,303
Options on Issue: 3,657,500 (at varying exercise prices and expiry dates)

Market Listings:

Australian Securities Exchange (ASX Code: ATX)


Directors:

Dr Warwick Tong, Chairman, Independent Non-Executive Director
Simon Wilkinson, Executive Director & CEO
Dr Robert Peach, Independent Non-Executive Director
Dr Christian Behrenbruch, Independent Non-Executive Director
Dr Christopher Burns, Independent Non-Executive Director
Andrew J. Cooke, Independent Non-Executive Director and Company Secretary


Management:

Simon Wilkinson, CEO
Jeff Carter, CFO
Dr Mark Devlin, Chief Scientific Advisor
John Lambert – Operations Manager


Registered Office:

Suite 226, 55 Flemington Road,
North Melbourne VIC 3051
Australia


Auditors:

Grant Thornton Audit Pty
GPO Box 4736
Melbourne 3001
Australia



Download: